A newly published study by UConn researchers confirms the  potential of reprogramming cells by cell fusion. 
The technique can create stem  cells for use in research, without harming embryos.
The study is likely to intensify mounting scientific interest in  reprogramming ordinary adult cells – somatic cells – back to their pristine  condition when they were stem cells in the embryo. 
The researchers, led by Theodore Rasmussen of UConn’s Center for  Regenerative Biology; Rachel O’Neill of the Department of Molecular and Cell  Biology; and Winfried Krueger of the UConn Health Center’s Department of  Genetics and Developmental Biology, reported their findings in the online  edition of Stem Cells, a  highly regarded journal that focuses on stem cell research. Dominic Ambrosi, a  doctoral student in molecular and cell biology, is first author on the paper.
“Our results show conclusively that factors in embryonic stem  cells can reprogram the somatic genome, providing a possible avenue to create  pluripotent stem cells without cloning,” says Rasmussen. 
Stem cells are the master cells that develop into the many  different types of specialized cells that make up the body. 
The potential of  embryonic stem cells to become virtually any kind of cell in the body is known  as pluripotency.
Currently, the only sure way to get pluripotent stem cells is to  extract them from surplus frozen embryos or from embryos created through  nuclear transfer – a procedure also known as therapeutic cloning.
Either way,  the process is controversial, because extraction destroys the embryo; critics  regard this as tantamount to abortion.
But recent studies have shown that pluripotency may exist in  certain cells that aren’t in embryos. 
ecause every cell in the body 
has the same genetic makeup, or DNA, the process of development starts with a  cell that could become anything, but specializes to become liver, or brain, or  heart, or muscle, or skin.
To become specialized, cells acquire different patterns of gene  expression, with some genes turned on while others remain silent. 
Scientists have hypothesized that if the patterns of gene  expression that produce specialization could be undone, and the process were  run in reverse, cells from liver, heart, brain, muscle, or skin could be  returned to stem cells like those from which they began.
Reprogramming seeks to switch on or off the appropriate genes to  transform an adult cell back to the equivalent of an embryonic stem cell. 
This  method could, in theory, mass produce stem cells while bypassing entirely the  problems posed by the use of frozen or cloned embryos.
  
                              
	
|  | 
| Professor Theodore Rasmussen examines a cell culture in his lab. | 
| Photo by Jordan Bender | 
The research published by Rasmussen and his colleagues at the  Center for Regenerative Biology and the Health Center is based on mouse cells. 
	Following earlier experiments that demonstrated adult cells could be  reprogrammed back into pluripotent stem cells, the UConn researchers blended  mouse embryonic stem cells with mouse adult cells in a special chemical  mixture.
After 12 days, several hybrid cell colonies were identified and  selected for further culture. From these, the team was able to establish four  stable stem cell-like lines, which they used to study gene expression from the  hybrid cells.
Monitoring the hybrid cells, the UConn team discovered patterns  of gene expression that made it clear the cells in the clusters were not simply  the sum of the expression patterns of the parental fusion partners. 
Some genes 
were silenced, while others were activated, demonstrating that 
the adult cells had been reprogrammed.
Rasmussen says the UConn researchers chose the mouse for their  study because its genome – the entire DNA sequence of an organism – has been  mapped, 
and that is key to understanding the structure, organization, and function of  DNA in mouse 
chromosomes.
“Now we can look at which genes are being expressed and get an  idea of which genes are important for reprogramming because we know the  complete DNA sequence of the mouse genome in the somatic cells,” Rasmussen  says. 
“We can distinguish the gene expression that arises from chromosomes of  somatic cell origin from gene expression arising from chromosomes of embryonic  stem cell origin.
“In future studies, the next step will be to try and manipulate  those genes,” he adds.
If scientists can understand the process, the information may  ultimately provide a basis for comparative studies with human embryonic stem  cells.
“We may be able to produce reprogrammed human cells someday soon,  based on the knowledge that we have obtained with the mouse system,” Rasmussen  says.
 “Such an advance could lead to the production of pluripotent human cells  with therapeutic value that will not be rejected by the prospective patient’s  own immune system.”